Sugi Predict

Sugi Predict / Compounds / SCHEMBL555256

SCHEMBL555256

SCHEMBL555256

CC(C)(C)OC(=O)N[C@@H]1CCCC[C@@H]1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.50
▸ CA1 P00915 3/20 0.49
▸ CA2 P00918 3/20 0.49
▸ MMP2 P08253 2/20 0.49
▸ MMP9 P14780 2/20 0.49
▸ CA12 O43570 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ MMP1 P03956 1/20 0.49
▸ MMP3 P08254 1/20 0.49
▸ MMP8 P22894 1/20 0.49
▸ MMP13 P45452 1/20 0.49
▸ GAA P10253 2/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ ANPEP P15144 1/20 0.41
▸ ERAP2 Q6P179 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ HDAC4 P56524 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30191451 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL1693182 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL3343104 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL3344958 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL555255 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL765453 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL16125648 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL1045289 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL21032211 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL23463705 0.98 BTK (0.49) BTKCA1CA2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116836032-A Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine 泰州葛林美克医药科技有限公司 2023-10-03 — — CN claimed
CN-116836032-B Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine 泰州葛林美克医药科技有限公司 2025-07-18 — — CN disclosed
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-04-17 — — US disclosed
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2024-11-21 — — US disclosed
EP-4436960-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-10-02 — — EP disclosed
CN-113614095-B Alkylboronic acids as arginase inhibitors 广东新契生物医药科技有限公司 2024-08-23 — — CN disclosed
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2024-08-20 — — US disclosed
CN-115028553-B Preparation method of chiral N-Boc/Cbz-cis- (1R, 2S) -cyclohexanediamine 上海瀚鸿科技股份有限公司 2024-03-26 — — CN disclosed
CN-116836032-A Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine 泰州葛林美克医药科技有限公司 2023-10-03 — — CN disclosed
CN-116836032-A Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine 泰州葛林美克医药科技有限公司 2023-10-03 — — CN disclosed
US-20040077645-A1 Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) 2004-04-22 — — US disclosed
US-6706712-B2 RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-16 — — US disclosed
EP-1371376-A1 ANTIPRURITICS Nippon Shinyaku Co., Ltd. (JP) 2003-12-17 — — EP disclosed
EP-1368349-A1 XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-12-10 — — EP disclosed
US-20030119855-A1 Heterocycle derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2003-06-26 — — US disclosed
EP-1306372-A1 HETEROCYCLE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2003-05-02 — — EP disclosed
US-20030004151-A1 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-02 — — US disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP disclosed
US-20020198205-A1 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-12-26 — — US disclosed
WO-2002068420-A1 XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN BTK 2/4885CA1 4319/4885CA2 3199/4885
US-20030004151-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 BTK 3233/4885CA1 1194/4885CA2 1252/4885
US-20030119855-A1 Heterocycle derivatives and drugs OPRL1, OPRK1, OPRD1 BTK 673/4885CA1 2568/4885CA2 843/4885
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 BTK 2/4885CA1 4239/4885CA2 3053/4885
US-20020198205-A1 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions DPP4, DPP3, DPP7 BTK 3419/4885CA1 896/4885CA2 1018/4885
US-20040077645-A1 Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment DPP4, DPP3, DPP7 BTK 2285/4885CA1 1160/4885CA2 1699/4885
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection CYP3A5, CYP3A43, CYP51A1 BTK 3191/4885CA1 3398/4885CA2 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.